<DOC>
	<DOCNO>NCT02059616</DOCNO>
	<brief_summary>The purpose study explore optimal dose fixed-dose combination candesartan cilexetil amlodipine besylate examine safety efficacy combination therapy compare monotherapy patient essential hypertension .</brief_summary>
	<brief_title>A Phase 2 Dose Selection Trial Candesartan Cilexetil Amlodipine Besylate Treat Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Male female age ≥ 19 ≤ 75 year old Subject mildtomoderate uncomplicated essential hypertension Subject voluntarily agree participate trial sign write informed consent form , listen purpose , method , effect clinical trial Subject severe hypertension ( siDBP ≥ 115 mmHg siSBP ≥ 185 mmHg ) Subject difference mean blood pressure 10mmHg siDBP 20mmHg siSBP arm screen visit Subject know suspect secondary hypertension [ include limited following : renovascular hypertension , adrenal medullary cortical hyperfunction , coarctation aorta , primary hyperaldosteronism , unilateral bilateral renal artery stenosis , Cushing 's disease , pheochromocytoma , polycystic kidney disease , etc . ] Subject symptomatic orthostatic hypotension ( sudden fall siDBP least 10 mmHg siSBP least 20 mmHg standing compare blood pressure sit supine position ) Subject Type 1 diabetes mellitus OR Type 2 diabetes mellitus poor glucose control ( define subject insulin treatment , HbA1c &gt; 9.0 % , modification oral antihyperglycemic medication regiment within past 12 week prior Visit 1 ) Subject severe heart disease ( Congestive heart failure ( NYHA Class IIIIV ) , ischemic heart disease within past 6 month ( unstable angina , myocardial infarction ) , peripheral vascular disease , history Percutaneous Transluminal Coronary Angioplasty Coronary Artery Bypass Grafting ) Subject clinically significant ventricular tachycardia , atrial fibrillation , atrial flutter clinically significant arrhythmia Subject hypertrophic obstructive cardiomyopathy , severe obstructive coronary artery disease , aortic stenosis , haemodynamically relevant stenosis aortic mitral valve Subject severe cerebrovascular disease ( history stroke , cerebral infarction , cerebral hemorrhage within past 6 month ) Subject history waste disease , autoimmune disease ( rheumatoid arthritis , systemic lupus erythematosus ) , connective tissue disease Subject know moderate malignant retinopathy ( history retinal sign hemorrhage , visual impairment , retinal microaneurysm , etc . within past 6 month ) Subject follow clinically significant laboratory abnormality : AST ALT &gt; 3 x Upper Limit Normal ( ULN ) Serum Creatinine &gt; 1.5 ULN Serum potassium &lt; 3.5 mmol/L &gt; 5.5 mmol/L Subject surgical medical condition gastrointestinal tract might significantly alter absorption , distribution , metabolism excretion drug Subject history malignant tumor include leukemia lymphoma within past 5 year ( except localize basal cell carcinoma skin ) Subject chronic inflammatory condition need chronic antiinflammatory therapy Subject chronic kidney disease dialysis Subject cardiogenic shock Subject require concomitant use antihypertensive contraindicate drug entire study period Subject know suspected contraindication , include history allergy hypersensitivity ARB dihydropyridine derivative Subject previously experience symptom characteristic angioedema treatment ACE inhibitor ARB Pregnant woman , lactate mother , woman suspect pregnant , woman wish pregnant study , woman childbearing potential use medically acceptable method contraception ( oral contraceptive , intrauterine device , condom , etc . ) , except woman surgical sterilization . Premenopausal woman surgically sterilize must negative pregnancy test result Visit 1 maintain acceptable method contraception throughout study . Periodic abstinence ( eg , symptothermal , calendar , postovulation method ) , hormonal contraceptive acceptable method contraception History drug alcohol abuse within past 1 year Use investigational product within past 4 week Subject judge unsuitable participate study opinion investigator</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>